June 13, 2024 10:34 AM EDT
News Briefing

Avid­i­ty’s $300M of­fer­ing; Rap­port rais­es $174M

Lei Lei Wu

News Reporter

Plus, news about Replim­mune, No­vo Nordisk and Bios­plice:

Avid­i­ty Bio­sciences is look­ing for $300M in stock sale: The RNA com­pa­ny is plan­ning a $300 mil­lion …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Director of IT, Security

Viridian Therapeutics

Waltham, MA, USA

TRENDING NOW

In sur­prise, study sug­gests Covid mR­NA vac­cines may boost can­cer im­munother­a­py ef­fi­ca­cy

Ex-Kite lead­ers step in at Kyver­na as CEO ex­its af­ter land­ing year's sec­ond-biggest IPO

BioN­Tech rolls out Phase 2 lung can­cer da­ta as VEGF bis­pecifics take cen­ter stage

Pfiz­er tees up Phase 3 test in weight man­age­ment — but in an un­ex­pect­ed area

Im­mat­ics los­es Bris­tol My­er­s' sup­port on Phase 1 bis­pe­cif­ic T cell en­gager

sponsored

Break­ing down si­los with a new quan­ti­ta­tive ap­proach to drug de­vel­op­ment

A service from the Financial Times